John Wheatley
Family Medicine · Louisville, KYNPI 1962458737
Payments from drug & device makers
Across 126 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$347
- AbbVie$315
- AstraZeneca$221
- Pfizer$195
- GSK$155
- Boehringer Ingelheim$126
- plus $536 from 18 others
What the payments were for
- Food & beverage$1,896100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $347 |
| AbbVie(2 entities) | 23 | $315 |
| AstraZeneca | 6 | $221 |
| Pfizer | 13 | $195 |
| GSK | 11 | $155 |
| Boehringer Ingelheim | 9 | $126 |
| Amgen | 8 | $110 |
| Novartis | 6 | $82 |
| Amarin Pharma, Inc. | 5 | $63 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Si-bone, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Abbott | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Bayer | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Merck | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,896 in reported general payments places this provider in the 65th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $13,862 |
| Levothyroxine Sodium | 58 | $769 |
| SynthroidLevothyroxine Sodium | 11 | $734 |
| Metoprolol Succinate | 75 | $711 |
| Atorvastatin Calcium | 99 | $694 |
| Potassium Chloride | 23 | $621 |
| Pantoprazole Sodium | 53 | $518 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 25 | $368 |
| Glipizide ErGlipizide | 14 | $299 |
| Omeprazole | 45 | $272 |
| Furosemide | 46 | $235 |
| Metformin Hcl | 39 | $226 |
| Amlodipine Besylate | 65 | $212 |
| Pravastatin Sodium | 28 | $207 |
| Rosuvastatin Calcium | 36 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $195 | $13,86211 claims |
| AbbVieSynthroid | $315 | $73411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$1M
- Michael LovelaceLouisville$244K
- Suraj GathaniLouisville$69K
- Mandy WhittLouisville$38K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.